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1INTRODUCTION
Psoriasis is a common, immunologically mediated inflammatory
dermatosis with genetic predisposition, characterized by erythematous
scaly plaques involving the scalp and extensors of limbs affecting 0.5 to
1.5% individual’s worldwide.
Psoriasis evokes considerable physical, psychological and social
morbidity among the affected individuals.
This common dermatosis is extremely variable in clinical
manifestations by morphology and extent of involvement, ranging from
innocuous lesion to widespread life threatening pustular and erythrodermic
forms. It can affect any area including palms, soles and genitalia.
Several treatment modalities are currently available and many
guidelines have been formulated all over the world. The treatment is
mainly suppressive aimed at inducing remissions and improving the
patient’s quality of life.
The  treatment  is  also  depends  on  the  patient’s  own  perceptions  of
disability occurring due to the disease.
2Routinely for limited plaque psoriasis coal tar, topical
corticosteroids, dithranol, calcipotriol and topical photochemotherapy are
administered.
For extensive psoriasis UVB, PUVA, PUVASOL, methotrexate,
hydroxyurea, acitretin and cyclosporine are preferred.
Disease modifying agents such as etanercept, infliximab and other
biological may be required in resistant cases.
This study was designed to compare the therapeutic efficacy of
PUVA,  PUVASOL and  NBUVB in  the  treatment  of  chronic  plaque  type
psoriasis involving more than 20%   body surface area.
3HISTORICAL REVIEW
        Psoriasis is a disease of the skin, characterized by a chronic relapsing
and variable clinical features. The cutaneous lesions are so distinct there
by a clinical diagnosis is easy to make.1 Psoriasis is a polygenic disease.
Various triggering factors such as infections, trauma, medications, may
elicit a psoriatic phenotype in a predisposed individual.2
The earliest description of psoriasis is given at the beginning of
medicine in the Corpus Hippocraticum. This work was edited in
Alexandria 100 years after the death of Hippocrates (460-377 BC). 3
Hippocrates used the term “psora” and “lepra” for conditions,
recognized as psoriasis. 1
The original description of psoriasis is attributed to Celsus in 35 to
40 AD. During Biblical times and there after psoriasis was confused with
syphilis, leprosy and other skin diseases.
In the second century AD the term “psoriasis” was introduced by
Galeo. He described an itchy skin condition characterized by scaling of the
eyelid, scrotum and corner of the eyes. 2
In 1808, Robert Willan an English physician made the first
description of psoriasis and its different manifestations. 4
4      In 1841, Hebra definitely separated the clinical features of psoriasis
from that of leprosy.
Robert William (1757-1812) was the first person to describe
psoriasis as a clinical entity. He described psoriasiform lesions as two
different groups,
1. Discoid lesion - “Lepra Graecorum”
2. Polycyclic confluent lesion - “Psora Leprosa”
The later is called as psoriasis. 1
1n 1841, a Viennese physician Ferdinand Von Hebra provided a
complete precise description of psoriasis.
Heinrich Auspitz (1835-1886) called attention to the bleeding points
on  removal  of  scales,  which  is  a  characteristic  sign  of  psoriasis  known
today by his name. 5
In 1876, Heinrich Koebner described koebner’s phenomenon, a
most significant observation on the natural history of psoriasis. 6
Exposure  to sunlight is the oldest treatment for psoriasis. 2 In 1878,
a British dermatologist Balmanno squire introduced the chrysophonic acid
ointment(chrysaeobin) for the treatment of psoriasis.
5In 1895,  Sir Jonathan Hutchinson described the rupial form of
psoriasis and the  use of  Fowlers solution in the treatment of psoriasis.
In 1898, Munro described the microabscess of psoriasis which today
bears his name.7 In 1910, Leovan Zumbusch described generalised
pustular psoriasis which is known as Von Zumbusch disease. 8
In 1916, Pau Gerson Unna,established the use of anthralin in the
treatment of psoriasis. 9   In 1925,  Goeckerman reported the combination
therapy of crude coal tar with UV B irradiation. 10
In 1926, a Russian dermatologist Woronoff  immortalized in the
psoriatic  literature for description of a pale zone around a plaque of
psoriasis referred to as “Woronoff”s ring”. 11
In 1927, Frank kogoj of Yugoslavia described the spongiform
pustule. 12 In 1950, Philip Hench received Noble prize for the discovery of
cortisone.
In 1951, Gubner was the first to use Aminopterin for the treatment
of psoriasis. Later it was replaced by its more stable analogue
Methotrexate. 13
6In 1953, John Ingram established the dithranol regimen and first day
care centre for psoriatic patients. 14 In 1970, Leavell reported the use of
hydroxyurea in the treatment of psoriasis.
In  1974,  Parrish  J.A.et  al  reported  the  combined  use  of  8-
methoxypsoralen and UV A in psoriasis.They coined the term
photochemotherapy and acronym “PUVA”. 15
In  1976,  Fischer  demonstrated  the  effect  of  UVB  alone  in  the
treatment of psoriasis.16  In  1982,  first  use  of  Methotrexate  and  UV  B
reported. 17
In 1980, Parrish and Jaenicke demonstrated that wavelength near
313 nm were most efficient for clearing psoriasis. 18 In 1986, Morimoto
reported the use of topical calcipotriol , which is an vitamin D metabolite
in the treatment of psoriasis.
And for this century(2000),more technological treatments
discovered such as Biological and Laser treatments.
PSORIASIS-QUANTUM OF PROBLEM:
Psoriasis is universal in occurrence.The prevalence of psoriasis
varies from 0.1 to 2.84 % in different epidemiological and clinical studies.
19
7     The incidence ranges from 0.3% in China,1.4% in US 2.3% in
Sweden and 2.8 % in Faroes. 20
      In India the incidence ranges from 0.8-5.6% in dermatology clinics
and Hospitals. Psoriasis is rare in West African and North American
Blacks. 21-25
      The age of onset of psoriasis varies. In two studies the highest
incidence was in the age groups of 15-45 years and 11-40 years.19 Females
develop psoriasis earlier than males. 26
In 1986, Kaur reported the mean age of onset for males and females
were 36.9±15.10 and 29.34±15.10 years respectively. Greater is the
probability of a family history of psoriasis when the onset is earlier. 27
In most Indian studies, a higher prevalence is noted in males(2.4%)
than in females(0.8%).22,23 In 1967, Hellgren in a study of 39000 subjects
found that 6.4% of the relatives of psoriatic patients has psoriasis.
There are two clinical presentations of psoriasis.
     Type 1 disease (Hereditary form) and type 2 disease (Sporadic
form). Type 1 disease is more common and it is associated with HLA
CW6 with more severe and recurrent course. Type 2 disease starts later in
life without any family history or HLA CW6 association.
8ETIOLOGY AND PRECIPITATING FACTORS:
The cause of psoriasis is not fully understood.But there are many
factors that precipitate psoriasis.They are
1. Trauma:
          Psoriatic  lesion  may  occur  at  the  sites  of  injury  to  the  skin  as  a
koebner phenomenon.The trauma may be physical, chemical, mechanical
or allergic.
2. Infection:
         In children with guttate psoriasis,56-85%  have precedent evidence
of streptococcal infection like upper respiratory infection or tonsillitis. 28
HIV infection is associated with exacerbation of psoriasis.
3.  Season:
          Sunlight and hot weather are reported to be beneficial, while cold
weather exacerbates psoriasis. 29
4.   Metabolic factors:
Hypocalcemia and dialysis have precipitated psoriasis. 30
95.  Endocrine factors:
         There are peaks of incidence of psoriasis at puberty and at
menopause. Remission of psoriasis occur during pregnancy and there is
exacerbation during the post partum period. 31
6.  Psychogenic factors
Stress may exacerbate psoriasis. The disease can cause ‘depression’
in the patient, which further exacerbates psoriasis. 32
7.  Alcohol:
         Alcoholics who have psoriasis, drink excessive amounts of alcohol
and subsequently have a flare of disease. 33
8.  Anatomic sites:
       In chronic stationary psoriasis, the scalp is most frequently
involved, followed by knees and elbows. In guttate psoriasis, the proximal
extremities and trunk are affected. 34
9.  Drugs:
Administration of lithium, beta blockers, antimalarials, clonidine,
amiodarone, potassium iodide, digoxin,  gemfibrosil, terfenadine,
trazodone, penicillin, NSAIDS and sudden withdrawal of systemic steroids
can exacerbate Psoriasis. 35
10
PATHOGENESIS
The literature of recent years contains a vast array of investigative
observations and data relating to the pathogenesis. While still
inconclusive, they emphasize the complexity of the disease process and
broaden our understanding of clinical features, course and treatment of the
disease.
1)  Epidermal kinetics :
The epidermal proliferation in psoriasis was described by Van Scott
and Ekel (1963). There is shortening of the epidermal germinative cell
cycle, an increase in the number of cells in the proliferative pool and
shortening of the epidermal turnover time in psoriatic lesion. Epidermal
proliferation and epidermal growth factor (EGF) receptor expression
appears to be increased in psoriatic lesion.36
2)  Leucocyte attractants:
The presence of dermal and intra-epidermal neutrophil infiltrates in
psoriatic lesions suggests that one or more neutrophil attractants are
released locally. The neutrophil attractants recovered from psoriatic lesion
include leucotriene B4 (LTB4), monohydroxy arachidonic acid metabolite,
12 (R) hydroxyl-5, 8, 10, 14eicosatetraenoic acid (12 [R] – HETE), ether-
linked phospholipid, platelet activating factor, interleukin 8 or neutrophil
activating peptide (NAP) and the complement product C5 a des arg.
11
3)   Polyamines:
Polyamines are low molecular weight organic amines. Polyamines
like spermidine, spermine and putrescine are involved in DNA synthesis
and cell proliferation. Antipsoriatic agents such as topical steroids,
anthralin, PUVA and retinoids have been found to reduce epidermal
polyamine synthesis.
4)   Cyclic Nucleotides:
Increased levels of cAMP cause inhibition of cell activity, whereas
increased cGMP levels may be stimulatory. Alterations in cGMP / cAMP
ratios are therefore considered to be of possible importance in the genesis
of the hyperproliferative changes in psoriasis.
5)  Proteinases:
Proteinases like plasminogen activator and various cathepsin and
their inactivating antiprotease like alpha-1 antitrypsin may play a role in
epidermal proliferation and differentiation.
6)   Immunological Mechanism:
Following trauma or infection, vasodilation occurs and is
accompanied by an influx of neutrophils into the epidermis. Proteolytic
enzymes released by neutrophils unmask the stratum corneum antigen.
Stratum corneum antibodies leak into the epidermis and fix the newly
12
exposed antigen. The antigen-antibody reaction triggers the complement
cascade and further inflammatory response.37
Normally basal cell nuclear material is not recognized by the
immunological system. A genetic defect or a virus leads to malfunctioning
of such a clone of suppressor cells leading to recognition of basal cell
nuclear material as antigen.
Subsequently antibodies are formed against this antigen leading to
immunological response which results in epidermal cell proliferation.
CLINICAL CLASSIFICATION:
        1.  Chronic plaque psoriasis
        2.  Guttate psoriasis
        3.  Erythrodermic psoriasis
        4.  Pustular psoriasis
        5.  Psoriasis unguis
        6.   Mucous membrane psoriasis
        7.    Psoriatic arthritis
        8.    Regional variations:
               Scalp, face, flexures, scrotum, napkin area, palms and soles.
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         9.   Follicular psoriasis
         10.  Rupioid , Elephantine and Ostraceous psoriasis
         11.  Unstable psoriasis
         12.  Atypical  forms:
              a. Linear and Zonal forms
              b. Sebopsoriasis
              c. Ocular  lesions.
AUSPITZ’S SIGN:
     Auspitz’s sign -  when psoriatic scales are scrapped with a glass
slide punctate bleeding points appears . This was described by Heinrich
Auspitz.
SEVERITY:
  Psoriasis is usually graded as mild ( less than three percent of the
body), moderate ( three to ten percent of the body) or severe (more than
ten percent of the body). 38
Degree of severity is generally based on:
        1.  Proportion of BSA affected
14
2.   Activity of lesions as evidenced by extent of scaling, thickness
and redness
        3.  Therapeutic response to prior treatment
        4.  Impact of  disease on individual.
PHOTOCHEMOTHERAPY:
PUVA THERAPY:
Psoralen is used topically or taken orally to sensitize the skin, then
the skin is exposed to UVA.
       Photo chemotherapy ( PUVA ) using psoralen and high intensity
long wave ultra violet rays is an effective treatment for chronic plaque
psoriasis.
SPECTRUM OF ELECTROMAGNETIC WAVES: 39
Infra red rays and radio waves      > 700 nano meter
Visible light                                  400 – 700nano meter
Ultra violet   A                              320 – 400 nano meter
Ultraviolet    B                               280 -320 nano meter
Ultra violet   C                              100 -280 nano meter
15
Gamma & Cosmic rays                < 100 nano meter
EFFECTS  OF   ULTRAVIOLET  RADIATION  ON  SKIN 40
Photobiological reactions occurs by interaction of  light with the
skin.
Photobiological  reactions takes place in several steps.
STEP 1:Absorption of light by chromophore.
             Light has to be absorbed by molecules, such as proteins or DNA,
which is known as chromophores. Absorption  spectrum of the
chromophore is the specific wavelength of the light absorbed by each
chromophore. Absorption maxima of the chromophore is the wavelength
which has the greatest probability of absorption.
STEP 2 : Excitation to singlet/triplet state
      Chromophore gets excited into singlet and triplet states after
absorption of light.
STEP 3 : Formation of photoproduct
      Triplet state initiate a chemical change in the chromophore there by
transforming  it into photoproduct.
STEP 4 : Initiation of  biochemical reactions
16
      The photoproducts may initiate a complex biochemical reactions
such as induction of gene products, enzymatic repair and DNA replication.
STEP 5 : Cellular response
      Above mentioned biochemical reactions culminate in a cellular
responses such as apoptosis, mitosis and differentiation.
STEP 6:Clinical response
      The final step of photobiological reaction is the clinical
manifestations in the form of hyperplasia, erythema, formation of tumour
etc.
PSORALEN:
Psoralen belongs to the family of  Furocoumarins  and it is the
parent compound too. The furan ring common to Psoralen and Coumarins
makes them structurally related. Psoralen occurs naturally in the seeds of
psoralea corylifolia (Indian plant) ,  ammi majus (Egyptian plant) as well
as in the fig, celery, parsley, west Indian satinwood and cloves. 41
17
      The medical use of these plants in the treatment of vitiligo by
ancient Egyptians dates back to 1500 B.C and by Indians to1400B.C.
CHEMISTRY:
Psoralen  commonly used in photochemo therapy is
8-methoxypsoralen (xanthotoxin, Methoxsalen) Which is a plant product.
Synthetic  preparations are available , as 4-5-8 trimethyl psoralen
(trioxsalen, TMP) and it is less phototoxic. Newer psoralens are 5 methoxy
psoralen (bergapten, angelicin). 42 Photobiological activity of angelicin is
low. 43
PHARMACOLOGY:
        When taken orally, 8 methoxypsoralen is absorbed from the G.I.T.
One hour after intake the photo sensitiveness starts, reaching peak at about
two hours and photosensitive effect wears off after about eight  hours. 44
18
        After oral administration the drug is metabolized in the liver by
hydroxylation and glucuronide formation. More than 90% of the drug is
excreted in the urine with in 12 hours. 45
The half life of  Methoxsalen is one hour. It is excreted rapidly
which helps in preventing photosensitivity. 46
Unique features of psoralen pharmacology are
1. Insolubility in water
2. Physical formulation influences absorption
3. Food decreases absorption
4. First-pass effect through liver  and
5. Large interindividual variation in absorption.
Dietary influences may be important as a fat rich meal may delay or
reduce the absorption of 8-MOP. 47
MECHANISM OF ACTION: 48
Psoralen  causes   photosensitization   of   skin   by   two  different
reactions. When skin is exposed to ultraviolet A light after intake of
Psoralen following reactions occur.
     1. TYPE 1: Anaerobic , which does not require O2  and site of cellular
damage is deoxy ribonucleic acid.
19
    2. TYPE 2: Sensitized  dependent, involves formation of  reactive O2
species such as O2, O 2 - and free radicals.
In these modes of reactions, reactive form of  Psoralen is in the
triplet state.
 The sites of reaction are:
  1. DNA & chromatin
  2. Epidermal, dermal and endothelial cell membranes.
  3. RNA, lysosomes, enzymes in cytoplasm of cells.
  4. Membrane lipids involving a photodynamic reaction.
Major  photochemical reaction of  Psoralen is formation of  mono
and  bifunctional  adducts  with  pyrimidine  bases  in  the  DNA,  which
inhibits  Deoxy riboneucleic acid synthesis and  multiplication of cells.
Psoralen ultraviolet A therapy affects cells like the T lymphocytes
or neutrophils which play important role in pathology of  Psoriasis.
Following  PUVA  treatment  a decrease in number of  Tlymphocytes  has
been reported. 49
INDICATIONS: 50
1. Psoriasis
2. Vitiligo
20
3. Atopic dermatitis
4. Cutaneous T cell leukemia
5. Lichen planus
6. Urticaria pigmentosa
7. Graft versus host disease
8. Actinic prurigo
9. Nodular prurigo
10. Pityriasis alba
11. Preventive treatment for photosensitive dermatoses like :
a. Polymorphic light eruption
b. Chronic actinic dermatosis
c. Solar urticaria
d. Hydroa vacciniforme
e. Persistent  light reaction
12.  Miscellaneous:
Alopecia areata, acute and chronic pityriasis lichenoides,
lymphomatoid  papulosis and pityriasis rubra pilaris.
PROCEDURE: 48
0.6-0.8mg/kilogram  body weight of 8-Methoxy Psoralen  is
administered orally, and after 1 to 3 hours whole body is irradiated with
21
Ultra violet A.  According to skin typing or photo toxicity testing  initial
dose of UV A is predetermined.
Repeated exposures are necessary for clearance of the disease, if
pigmentation appears UV A doses have to be increased.After achievement
of satisfactory clearance of the disease dosage is reduced. The last UV A
dose is the maintenance dose.
PROTOCOL FOR PUVA THERAPY:
Since the introduction of  PUVA therapy in 1974,there are
numerous protocols have been used. They all are slightly different, but
share the same principle of  repeated and regular PUVA exposures.
All these protocols have 2 phases:
1. Clearance phase aiming at suppression of the disease.
2.  Maintenance phase by tapering to a minimum dose of therapy
to maintain and extend remission.
 Two protocols which are commonly used are
   1. American protocol
   2. European protocol
22
AMERICAN PROTOCOL: 51
The first exposure dose of therapy depends on the skin typing and it
is twice or thrice per week. Depending on the erythema production and
therapeutic response dose increments ranges from half to one and half
joules per square centimeter area.
EUROPEAN PROTOCOL: 52
First   minimum phototoxic dose ( MPD ) has to be determined then
treatment is administered and the MPD is the patient’s initial UV A dose.
Four treatments are given per week. In a week first two days therapy is
given, followed by rest on third day. Again therapy should be given on
fourth and fifth day. In the absence of development of erythema after four
treatments dose increment is performed in a range from half  to two joules
per square centimeter area.
AMERICAN EUROPEAN
Initial  dose  determination Skin  phototype MPD
No.of   weekly  treatments 2 4
Increments Predetermined
and  fixed
Individualized
and  flexible
No. of  weeks  required  for
clearing
12.7 5.7
No. of exposures 25 20
Cumulative UVA dose 245J/ cm2 96 J/ cm2
23
SKIN PHOTOTYPES: 53
1 Burns always, never tans
2 Burns always, tans sometimes
3 Sometimes burns, tans always
4 Never burns, but tans always
5 Moderate pigmentation
6 Deep pigmentation
Types 1 – 4 are determined by history and
Types 5 – 6 by physical examination..
Dose of  UVA radiation  for induction  phase  schedules 54
Skin type
UVA radiation dose  J/ cm2
Initial dose Increments   Maximum dose
1 0.5 0.5 8
2 1.0 0.5 8
3 1.5 1.0 12
4 2.0 1.0 12
5 2.5 1.5 20
6 3.0 1.5 20
24
Indian skin comes under 4 & 5 phototype and is usual to start with
2.0 J/cm2 and  increments of 0.5 – 1J/cm2 based on skin response.
MINIMUM PHOTOTOXIC DOSE ( MPD ):
Minimum phototoxic   dose  is  defined  as  the  lowest  dose  of  UV A
delivered  to  the  skin  after  ingestion  of  8-MOP   which  causes   a  well
demarcated erythema when small test areas of skin is treated with  large
doses  of  UV  A  (0.5  –  5  Joules/centimeter  square).  After   72  hours  of
testing, when a peak phototoxicity has reached, erythema readings are
performed.
Extra treatment may be needed for the lower limbs, where the
lesions respond slower. An additional  irradiation of 0.5 – 5 J/cm2 is
needed for these areas, the dose being  gradually increased.
Average of about 20 exposures is required for clearing,but varies
from 15 – 20. About 5-20 J/cm2 is the final clearance dose of UV
radiation, depending upon the skin type. For all skin types the average
cumulative dose of  Ultraviolet A needed to clear is 103 & 79 Joules per
square centimeter in two European trials. 55
Considerably higher mean cumulative Ultraviolet A dose (245
Joules per square centimeter) was noted in the US trial. 56
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      If no maintenance therapy is given, most of the patients presents
with relapse in the first month. In patients for whom  maintenance therapy
is given and stopped after two to three months, the relapse do not occur
immediately.  Later  group  remain  symptom  free   for  a  period  of   6-  12
months.57
During PUVA therapy goggles should be worn to protect the eyes. It
should be worn for 24 hours after therapy.
During treatment men should protect their genitals from UVA
exposure.
MAINTENANCE SCHEDULE FOR PUVA THERAPY:
Four treatments at weekly intervals,then
    Four treatments every other week,then
    Four treatments every third week,then
    Four treatments every fourth week,then
    Stop treatment or continue monthly.
CONTRAINDICATIONS: 58
ABSOLUTE:
    1. Pregnancy and lactation
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    2. Lupus erythematosus
    3. Severe hepatic failure
    4. Severe renal failure
    5. Xerodermo pigmentosum.
RELATIVE:
    1.  Children < 12 years of age
    2.  Previous exposure to x rays,arsenic
    3.  Personal or family H/O melanoma
    4.  Immuno suppressed patients
    5.  Cataract
    6.  Concomitant intake of phototoxic drugs like doxycycline,
sparfloxacin etc
SIDE EFFECTS: 59
SHORT TERM:
    1.   Erythema
    2.   Sunburn
    3.   Pruritis
27
    4.   Headache
    5.   Nausea
    6.   Koebner’s response
    7.   Dizziness
    8.   Drug eruption
    9.   Severe skin pain
   10.   Bronchial reaction
   11.   Contact allergy
LONG TERM:
    1.  Xerosis
    2.  Hyperpigmentation
    3.  Hypopigmentation
    4.  Photo ageing / Wrinkling
    5.  Chronic phototoxicity
     6.  Oedema of legs
     7.  Hypertrichosis
28
     8.  Nail changes like pigmentation, subungual hemorrhage & photo
onycholysis
     9.   Dyskeratotic or precancerous conditions such as Bowen’s disease,
Keratoacanthoma and Actinic keratosis.
     10. Cutaneous malignancy such as squamous cell carcinoma
     11. Cataract
     12. Malaise
     13. Depression
     14. Lack of concentration
     15. Insomnia
Certain skin conditions such as seborrhoeic dermatitis, lupus
erythematosus, bullous pemphigoid and acne are  aggravated  by  PUVA
therapy.
There are isolated reports of certain skin conditions linked with
PUVA therapy. They are malignant melanoma,hepatotoxicity, nephrotic
syndrome, hypotension, lichenoid eruption,  leukemia and exacerbation of
gouty arthritis.
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PUVA MONITORING GUIDELINES: 60
Baseline
Cutaneous:
Skin examination for actinic damage, premalignant lesions and skin
cancer
Skin biopsy of suspicious lesions
Ocular:
    Assessment of visual acuity
    Gross examination of the eye
    Examination of  cornea and lens using slit lamp
    Fundoscopy of retina.
Laboratory:
If there is positive findings on history or examination, evaluation of
renal and/or liver function
If  there  is  history  of  photosensitivity  or  other  evidence  of  collagen
vascular disease, evaluation for lupus vulgaris
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FOLLOW UP
Ocular:
If there are abnormal ocular findings at baseline or subsequently,
repeat eye examination yearly or more often
Cutaneous:
Educate the patient to examine monthly for skin cancer
Skin cancer screening of entire skin , at least yearly
NARROW BAND ULTRAVIOLET  B THERAPY
NBUVB is one of the novel therapeutic intervention now available
in treating several dermatological conditions. Fisher identified that narrow
band ultraviolet B radiation which has a wave length of 313 (311±2)
nanometer is efficient in clearing lesions. Even higher doses do not
produce notable erythema. 61
      Parish Jaenicke identified that clearance of psoriasis is better with
wavelength of 313nm. 62
      These observations lead to the invention of artificial fluorescent
lamps which contains phosphor  (TL-01) .
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       Van Weelden et al63  and Green et al64  used these lamps first in
1988  for treating Psoriasis.
MECHANISM OF ACTION:
     1.   Absorption of  UVB by nucleotides of  DNA leads to formation
of DNA photoadducts with pyrimidine dimers,which interfere
with cell cycle progression and induces growth arrest.
      2.   Releases prostaglandin which interferes expression and
production of interleukins and interferons. 65
      3.   Decreases the expression of Interleukin-12, Interleukin-
18,Interleukin-23 and Interferon – gamma, by inducing
apoptosis.66
      4.  Depletes T cells and NK cell activity.
      5.  Suppresses antigen presenting cells function.
      6.  Down regulates Th 17 cells. 67
INDICATIONS: 68
      1. Psoriasis
      2. Vitiligo
      3.  Atopic dermatitis
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      4.  Pityriasis rosea
      5.  Generalised lichen planus
      6.  Parapsoriasis
      7.  Seborrheic dermatitis
      8.  Pruritis
      9.  Mycosis fungoides
     10.  Pityriasis rubra pilaris
     11. Prurigo nodularis
     12. Acquired perforating dermatosis
     13. Scleroderma
     14. For prevention of photodermatoses.
CONTRAINDICATIONS: 69
       1.  Patients with photosensitivity.
       2.  History of exposure to arsenic.
       3.  History of exposure to ionizing radiation.
       4.  History of previous melanoma or multiple non melanoma skin
  cancer.
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       5.   Family history of melanoma
        6.  Persons with skin type 1
INSTRUCTIONS TO THE PATIENT:
        1.  Use of protective  eye  goggles.
        2.  In male patients shielding  genitals
        3.  Avoiding sun exposure unnecessarily.
PROCEDURE:
      On the basis of minimal erythema dose ( MED ) initial dose is
calculated. MED is the lowest dose of UVB producing defined erythema at
test  site.MED  is  determined  24  hours  after  exposure  of  UVB  on  the
back/buttocks of around 1cm× 1 cm. Initial dose  is generally 70%  of
minimal erythema dose. 70
Pai et al 71 determined the average MED in skin type 4 is 600
mJ/cm2   and in skin type 5 is 1100 m J/cm2 .
MED of  150   m J/  cm2 to 400 m J/cm2 is observed by Serish and
Srinivas. 72
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According to latest consensus as suggested by American academy
of Dermatology, the starting dose is decided by skin type and not based on
minimal erythema dose .
Dose recommendations  are as follows:
Skin
type
Initial Dose (milli
Joules/square centimeter)
Dose increments(milli
Joules/square centimeter)
1 130 15
2 220 25
3 260 40
4 330 45
5 350 60
6 400 65
Erythema response is graded as: 73
  1.  No erythema
  2.  Mild erythema –grade 1
  3.  Moderate and well defined erythema – grade 2
  4.  Severe painful erythema  persisting for > 24 hours –grade 3.
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No erythema-Dose is increased by 20 % of last dose.
Grade 1-Previous dose is maintained and subsequent dose increment
is reduced to 10 %.
Grade 2-Postpone one treatment, repeat previous  dose at next visit
and reduce to 10 % increment.
Grade 3-No treatment is offered until recovery and further treatment
is given by reducing exposure dose by half and 10 % increment there
after.74
If MED is calculated, dose increment should be 10 % of initial
MED for the initial 20 exposures and as per physicians discretion there
after.
Frequency of exposure is thrice or five times per week. 75
If dose is missed, NBUVB can be restarted.
         < 1 week - Maintain the last exposure dose.
         1-2 weeks - Restart at a dose < 25 % of the last dose.
         2-3weeks - Restart at 50 % depleted dose.
         >3 weeks - Restart from the previous starting dose.
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In India,approach commonly practiced involves a standard starting
dose of 280mJ/cm2 followed by stepwise increase of 20% depending on
the patient’s erythema response.
SIDE EFFECTS: 76
  1. Erythema
  2. Blistering
  3. Pruritis
  4. Reactivation of  herpes simplex
  5. Exposure keratitis and conjunctivitis
  6. Tanning
ADVANTAGES OF NB-UVB OVER PUVA THERAPY
     1.  No need for intake of psoralens. Hence side effects of psoralens can
be avoided.
     2. Useful in children under 12 years of age, where psoralen is
contraindicated.
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     3. Can be used in pregnancy and lactation, where psoralens are
contraindicated.
     4.  Can be used in elderly or those with poor hepatic or renal function.
     5.  No eye protection is necessary outside the chamber.
     6. Shorter exposure time as compared to PUVA therapy.
PUVASOL THERAPY
     Administration of psoralens followed by exposure to sunlight is
known as PUVASOL therapy. Trimethoxypsoralen is preferable for
PUVASOL therapy. 10 AM  to 2 PM is the best time for sun exposure.
MECHANISM OF ACTION
     Exact mechanism is not known, but it probably induces a
modification in circulating and  insitu lymphocyte population. It also
decreases thymus dependent lymphocytes. 77
      Here, both UV A & UV B in sunlight result in photoaugmentation
and photoaddition. 78, 79 Erythemogenic property of UV A may be additive
to subclinical or visible erythema induced by UV B. 80
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       During first sitting of therapy exposure to sunlight is limited to 10
minutes. Then duration of exposure can be increased  according to the
response.
ADVANTAGES:
   1.  Inexpensive
   2.  Patient need not travel for treatment
DISADVANTAGES:
   1.   Quantification of ultraviolet light is difficult.
   2.  The total dose of UV A that effectively reaches  skin varies with the
hour of the day, season, latitude and atmospheric conditions.
   3.  Need for privacy
   4.  Unnecessary presence of ultraviolet B, visible light and infrared rays
may lead to undesirable reactions.
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AIM OF THE STUDY
Aim of the study is to evaluate the therapeutic efficacy of
1.  PUVA( Psoralen ultraviolet  A therapy)
2.  NBUVB (Narrow band ultraviolet B therapy)
3.  PUVASOL( Psoralen ultraviolet  A solar  therapy)
in patients with chronic plaque type of psoriasis involving more than
20% of body surface area .
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MATERIALS AND METHODS
            Sixty patients of chronic plaque type psoriasis who attended the
psoriasis outpatient clinic at the Department of Dermatology, Rajiv
Gandhi Government General Hospital, Chennai were randomly selected
from August 2010 to September 2012.
          The diagnosis of psoriasis was made clinically by morphology of
lesions and Auspitz sign.
STUDY DESIGN :  Prospective study
INCLUSION CRITERIA
          Patients with chronic plaque type of psoriasis involving more than
20% of body surface area.
EXCLUSION CRITERIA
1.  Photosensitive disorders or history of photo damage
2.  Pregnant and Lactating women
3.  Children < 12 years of age
 4.  Previous or family history of malignant melanoma
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5.  H/O exposure to inorganic arsenic or ionizing radiation
 6.  Women contemplating conception.
 7.  Pustular,  erythrodermic psoriatic patients
All patients were explained about the disease, benefits and side
effects of the treatment were discussed with them.
Informal written consent was obtained from all patients before
initiation of treatment.
All patients were evaluated as follows
           1.  History
2.  General examination
3.  Systemic examination
4.  Dermatological examination
5.  Investigations-
     a. Complete hemogram
     b. Urine analysis
     c. Renal function test
     d. Serum calcium, uric acid
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     e. Liver function test
     f. Blood VDRL
     g. ELISA for HIV
6.   Ophthalmic evaluation
TREATMENT PROTOCOL AND METHODOLOGY
Sixty patients with chronic plaque type of psoriasis involving more
than 20% of body surface area were randomly allocated to any one of the
following three groups.
Group A: PUVA therapy, Group B: NBUVB therapy, Group C:
PUVASOL therapy.
GROUP A: PUVA THERAPY
? 20 patients were included in this group.
? Patients were asked to take Tablet. Trimethoxy Psoralen
20mg  in  empty  stomach  2  hours  prior  to   the  exposure  of
UVA therapy.
? All patients were asked to wear UV goggles when inside the
phototherapy unit and throughout the day thereafter.
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? Patients were advised to protect their genitalia.
? Initial UVA dose of  0.5 J/cm2 was started in all patients.
? Patients were advised to expose the affected parts.
? Patients were instructed to come out of the chamber when the
light switches off or when alarm beeps or if they became
uncomfortable during the treatment either due to burning or
stinging sensation of the skin.
? If the initial dose was tolerated, incremental dose of 0.5J/cm2
at each subsequent visit depending on the patients erythema
response.
? Treatment was given twice weekly (Monday and Friday).
? Patients were monitored regularly every week.
? Patients were instructed to report immediately if any of the
adverse effects were noted.
GROUP B: NARROW BAND UVB THERAPY
? 20 patients were included in this group.
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? All patients were asked to wear UV goggles when inside the
phototherapy unit.
? Patients  were advised to protect their genitalia.
? Initial UVB dose of  0.25 J/cm2 was started in all patients.
? Patients were advised to expose the affected parts.
? Patients were instructed to come out of the chamber when the
light  switches  off  or  alarm  beeps  or  if  they  became
uncomfortable during the treatment either due to burning or
stinging sensation of the skin.
? If the initial dose was tolerated, 20% incremental dose was
given at each subsequent visit depending on the patient’s
erythema response.
? Treatment was given thrice weekly on non consecutive days.
? Patients were monitored regularly every week.
? Patients were instructed to report immediately if any of the
adverse effects were noted.
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GROUP C: PUVASOL THERAPY
? 20 patients were included in this group.
? Patients were asked to take Tablet. Trimethoxy  Psoralen
20mg in empty stomach 2 hours prior to the exposure of
sunlight.
? Patients were asked to expose the affected area to sunlight for
ten minutes preferably between 11 A.M TO 2 P.M.
? Treatment was given thrice weekly on non consecutive days.
? Patients were monitored regularly every week.
FOLLOW UP
Patients were followed up every weekly, and PASI score was
calculated at 0, 4, 8, 12 and 16 weeks for all three groups. These were
compared and statically analyzed.
EFFICACY ASSESSMENT
               Severity and extent of psoriasis were evaluated using “Psoriasis
Area and Severity Index” (PASI) score.
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Severity of Erythema (E), Desquamation (D) and Induration ( I )
was recorded on a 5 point scale as follows.
       0 Nil
1 Mild
2 Moderate
3 Severe
4 Very severe
            The  area  of  involvement  was  recorded  on  a  7  point  scale  as
follows
0 Nil
1 <10%
2 10-29%
3 30-49%
4 50-69%
5 70-89%
6 90-100%
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PASI was calculated as follows
PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU +
       0.3(ET+IT+DT) AT + 0.4(EL+IL+DL)
A - Area
H - Head
U - Upper limb
T - Trunk
L - Lower limb
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OBSERVATION AND RESULTS
AGE DISTRIBUTION
         The mean age in our study group was 38.05 years in PUVA,
NBUVB group and 39.45 years in PUVASOL group. The minimum age in
PUVA, NBUVB and PUVASOL is 19, 17, 25 years respectively. The
maximum age in PUVA, NBUVB and PUVASOL is 61, 63, 58 years
respectively.
Table -1
Showing age distribution
Age N Mean Std. Dev Median Minimum Maximum
PUVA 20 38.05 12.05 37.00 19 61
NBUVB 20 38.05 14.30 36.50 17 63
PUVA SOL 20 39.45 8.77 37.50 25 58
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SEX DISTRIBUTION
Males were more in our study when compared to females.
            In PUVA group 70 % were males, 30 % were females. In NBUVB
group 65 % were males, 35% were females and PUVASOL group 50 %
were males, 50 % were females.
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Figure 1- showing Mean Age of patients in three
groups
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Table 2- showing Sex distribution
Groups Sex distribution (%)
Male Female
PUVA 70 30
PUVASOL 65 35
NBUVB 50 50
DURATION OF ILLNESS
  The duration of illness varies in three groups. In PUVA group
Duration  of  illness  varies  from  2  months  and  4  years.  In  NBUVB  group
duration varies from 1month to 8 years. In PUVASOL group duration of
illness varies from 2 months to 8 years.
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The mean duration in PUVA group is 15.78 months, NBUVB group
is 26.70 months, and PUVASOL group is 20 months.
Table 3
Showing duration of illness in three groups
Duration
(months)
N Mean Std. Dev Median Minimum Maximum
PUVA 20 15.78 14.21 12.00 2 48
NBUVB 20 24.00 26.70 10.50 1 96
PUVA SOL 20 16.90 20.76 9.00 2 96
0.0
5.0
10.0
15.0
20.0
25.0
PUVA NBUVB PUVA SOL
M
ea
n 
Va
lu
e
Study Group
Figure 3-Mean Duration of illness (months)
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FAMILY HISTORY
          Family history was present in 15% of patients in all three groups in
our study.
SCALP INVOLVEMENT
          Scalp involvement were present in 19 of our patients. 6 patients in
PUVA group, 8 patients in NBUVB group and 5 patients in PUVASOL
group.
Table 4
Showing percentage of scalp involvement
Group
Scalp involvement
Number of patients Percentage (%)
PUVA 6 30
NBUVB 8 40
PUVASOL 5 25
NAIL CHANGES
Nail changes were present in 21 of our patients, 7 in each group.
The Commonly noted nail changes were pitting ,  subungual
hyperkeratosis,  ridging.  More than one morphological nail changes were
present in a single patient.
In PUVA group
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7 had pitting,
                     2 had subungual hyperkeratosis,
                     1 had ridging.
In NBUVB group
7  had pitting,
                     3  had subungual hyperkeratosis.
        In PUVASOL group
                     7 had pitting,
                     3 had subungual hyperkeratosis,
                     1 had ridging.
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Pitting was the most common type of nail involvement in all three
groups of our study.
MUCOUS MEMBRANE
There was no mucous membrane involvement in our patients.
JOINT INVOLVEMENT
Joint  involvement  was  present  in  9  of  our  patients.  2  of  them  in
PUVA  group  (10%),  3  of  them  in  NBUVB  group  (15%),  4  of   them  in
PUVASOL group (20%) had joint involvement.
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Figure 4 - shows nail changes in three groups
PITTING SUBUNGUAL HYPERKERATOSIS RIDGING
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Table 5
 Showing joint involvement among three groups
Group
Number of
patients
Percentage (%)
PUVA 3 10
NBUVB 3 15
PUVASOL 4 20
           Figure 5 shows percentage of scalp, nail, and joint involvement in
PUVA, NBUVB and PUVASOL group.
0
5
10
15
20
25
30
35
40
45
50
PUVA NBUVB PUVA SOL
30
40
25
35 35 35
10
15
20
Pe
rc
en
ta
ge
Study Group
Figure 5 - Proportion ofscalp,nail and joint involvement
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Table 6
Chi-Square test to compare the proportions of scalp, nail and joint
involvement between the three groups
Variables
Group
Total
P-ValuePUVA NBUVB PUVA SOL
N % N % N % N %
SCALP
No 14 70.0 12 60.0 15 75.0 41 68.3
0.583
Yes 6 30.0 8 40.0 5 25.0 19 31.7
NAIL
No 13 65.0 13 65.0 13 65.0 39 65.0
0.999
Yes 7 35.0 7 35.0 7 35.0 21 35.0
JOINT
No 18 90.0 17 85.0 16 80.0 51 85.0
0.900*
Yes 2 10.0 3 15.0 4 20.0 9 15.0
Total 20 100.0 20 100.0 20 100.0 60 100.0
* Fisher’s exact test p-value
PASI REDUCTION
The following tables shows the mean PASI score  at baseline and
reduction of mean PASI score at 4 weeks, 8 weeks, 12 weeks, 16 weeks in
PUVA, NBUVB, PUVASOL groups.
The mean PASI score at baseline (Table 7) was 32.20 in PUVA
group, 31.04 in NBUVB group, and 34.59 in PUVASOL group. The
minimum  mean  PASI  score  at  baseline  in  PUVA,  NBUVB  and
PUVASOL group is 18.0, 15.2 and 18.9 respectively. The maximum mean
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PASI score at baseline in PUVA, NBUVB and PUVASOL group is 44.0,
47.8 and 44.0 respectively.
Table 7
Showing mean PASI score at baseline in three groups
PASI 0 N Mean Std. Dev Median Minimum Maximum
PUVA 20 32.20 7.59 32.40 18.0 44.0
NBUVB 20 31.04 9.02 31.35 15.2 47.8
PUVA SOL 20 31.59 8.04 33.00 18.9 44.0
The  mean  PASI  score  at  4  weeks  (Table  8)  was  20.76  in  PUVA
group, 20.82 in NBUVB group, and 24.96 in PUVASOL group.
The minimum mean PASI score at 4 weeks in PUVA, NBUVB and
PUVASOL group is 9.4, 10.1, and 12.4 respectively. The maximum mean
PASI score at 4 weeks in PUVA, NBUVB and PUVASOL group is 32.6,
35.6 and 42.6 respectively.
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Table 8
showing mean PASI score at 4 weeks in three groups
PASI 4 N Mean Std. Dev Median Minimum Maximum
PUVA 20 20.76 6.48 20.35 9.4 32.6
NBUVB 19 20.82 7.95 20.80 10.1 35.6
PUVA SOL 19 24.96 7.92 24.60 12.4 42.6
            The mean PASI score at 8 weeks (Table 9) was 10.54 in PUVA
group, 11.98 in NBUVB group, and 17.71 in PUVASOL group.
             The minimum mean PASI score at 8 weeks in PUVA, NBUVB
and PUVASOL group is 1.2, 1.5 and 6.2 respectively. The maximum
mean PASI score at 8 weeks in PUVA, NBUVB and PUVASOL group is
21.4, 26.4 and 38.4 respectively.
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Table 9
Showing mean PASI score at 8 weeks in three groups
PASI 8 N Mean Std. Dev Median Minimum Maximum
PUVA 18 10.54 4.95 9.85 1.2 21.4
NBUVB 19 11.98 7.10 10.80 1.5 26.4
PUVA SOL 18 17.71 50.71 15.40 6.2 38.4
The mean PASI score at 12 weeks (Table 10) was 3.18 in PUVA
group, 5.92 in NBUVB group, and 12.47 in PUVASOL group.
The  minimum  mean  PASI  score  at  12  weeks  in  PUVA,  NBUVB
and PUVASOL group is 0.0, 0.0 and 2.1 respectively. The maximum
mean PASI score at 12 weeks in PUVA, NBUVB and PUVASOL group is
10.5, 20.8 and 36.7 respectively.
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Table 10
Showing mean PASI score at 12 weeks in three groups
PASI 12 N Mean
Std.
Dev
Median Minimum Maximum
PUVA 18 3.18 3.30 2.15 0.0 10.5
NBUVB 19 5.92 5.61 4.60 0.0 20.8
PUVA SOL 18 12.47 4.64 9.90 2.1 36.7
The mean PASI score at 16 weeks (Table 11) was 0.38 in PUVA
group, 0.83 in NBUVB group, and 7.76 in PUVASOL group. The
minimum  mean  PASI  score  at  16  weeks  is  0.0  in  all  three  groups.  The
maximum  mean  PASI  score  at  16  weeks  in  PUVA,  NBUVB  and
PUVASOL group is 2.7, 4.6 and 32.4 respectively.
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Table 11
Showing mean PASI score at 16 weeks in three groups
PASI 16 N Mean Std.Dev Median Minimum Maximum
PUVA 18 0.38 0.81 0.00 0.0 2.7
NBUVB 17 0.83 1.51 0.00 0.0 4.6
PUVA SOL 18 7.76 3.20 3.60 0.0 32.4
From tables 7- 11 we inferred that there was gradual reduction in
PASI score in all three groups.
Table 12
Shows mean reduction in PASI score among three groups
Duration
Mean PASI score
PUVA NBUVB PUVASOL
Baseline        32.20        31.04       31.59
4 weeks        20.76        20.82       24.96
8weeks        10.54        11.98       17.71
12 weeks         3.18         5.92        12.47
16 weeks         0.38         0.83        7.76
In PUVA group the mean PASI score at baseline is 32.20 and it was
reduced to 0.38 at 16 weeks. In NBUVB group the mean PASI score while
enrolling in study was 31.04 where as it was reduced to 0.83 at 16 weeks.
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In PUVASOL group the mean PASI score was 31.59 at baseline and
it was reduced to 7.76 at 16 weeks of PUVASOL therapy.
Therefore the mean reduction of PASI score at 16 weeks is more in
PUVA group, followed by NBUVB group. PUVASOL has lesser
reduction in mean PASI score among three groups.
 Table 12 shows P values by comparing three groups with one
another. There was no statistically significant reduction in PASI score at 0,
4, 8, 12 and 16 weeks when PUVA and NBUVB are compared.
          When PUVA and PUVASOL groups are compared there is no
statistically difference in reduction in PASI score at 0, 4, 8 weeks. But at
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12 and 16 weeks there is statistically significant (P<0.001) reduction in
PASI score.
Table 12
Shows P values of PASI Score reduction when two
groups are compared
Variables
P-Values
PUVA vs
NBUVB
PUVA vs
PUVASOL
NBUVB vs
PUVASOL
PASI 0 0.579 0.903 0.695
PASI 4 0.933 0.255 0.184
PASI 8 0.627 0.024 0.101
PASI 12 0.150 0.001 0.035
PASI 16 0.694 0.001 0.001
          When NBUVB and PUVASOL groups were compared there was no
statistically significant difference in PASI score at 0, 4, 8, 12 weeks.
However at 16 weeks there is statistically significant PASI reduction
(P<0.001).
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PERCENTAGE REDUCTION OF PASI SCORE
Table – 13
Showing percentage mean reduction in PASI score in three groups
Duration PUVA NBUVB PUVASOL
Baseline 0 0 0
4 weeks 36.2 31.8 20.99
8 weeks 67.5 62.2 43.94
12 weeks 91.0 82.0 60.53
16 Weeks 98.9 97.9 75.44
       The above table shows that there is gradual increase in percentage
mean reduction of PASI score over weeks. When compared to baseline
mean PASI score there was 98.9 % reduction in mean PASI score at 16
weeks in PUVA group and 97.9% reduction in mean PASI score at 16
weeks in NBUVB group. In PUVASOL group there is 75.44% reduction
in mean PASI score at 16 weeks.
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          PUVA group has the maximum percentage reduction in mean PASI
score at 16 weeks, closely followed by NBUVB group. PUVASOL has
least reduction when all three groups are compared.
DURATION OF TREATMENT
             The average number of exposures and total duration of treatment
are tabulated below.
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Table 14
Showing number of weeks of exposure and
duration of treatment
Variables PUVA NBUVB PUVASOL
Average number  of
exposure
29.50 44.65 56.80
Duration of treatment
(weeks)
14.72 14.88 18.93
The  average  number  of  exposure  in  PUVA,  NBUVB  and
PUVASOL groups were 29.50, 44.65 and 56.80 respectively.
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Figure 8 - shows Mean number of exposures
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             The total duration of treatment in PUVA, NBUVB and PUVASOL
groups were 14.72 weeks, 14.88 weeks and 18.93 weeks respectively.
CUMULATIVE DOSE
The cumulative dose of ultraviolet A light for PUVA group is
21.0J/cm2 and the mean cumulative dose of narrowband ultraviolet B light
for NBUVB group is 17.10 J/cm2 .
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Figure 9 - shows Mean weeks of exposure
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RESPONSE TO THERAPY
Based on percentage reduction in PASI score the results were
graded as excellent (100%), good (75-100%), moderate (50- 75%) and
poor (< 50%).
Response to therapy in PUVA group
In PUVA group out of 20 patients 13 patients had complete
clearance at 16 weeks and 5 had good response. 2 patients discontinued
treatment at 8 weeks of therapy due to unknown reasons.
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Figure 10- shows mean cumulative dose in PUVA and
NBUVB group
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Table 14
Response to treatment in PUVA group
Results
No. of
patients Percentage
% reduction in PASI
score at 16 weeks
Excellent 13 72.22 100
Good 5 27.78 75-100
Moderate - - 50-75
Poor response - - <50
Discontinued 2 10.00 -
Therefore in PUVA group 72.22% of patients had excellent
response and 27.78 % of patients had good response at 16 weeks.
Response to therapy in NBUVB group
In  NBUVB  group  out  of  20  patients  12  patients  had  complete
clearance at 16 weeks and 5 had good response 1 patients had poor
response.  2 patients discontinued treatment at 8 weeks of therapy due to
unknown reasons.
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Table 15
Response to treatment in NBUVB group
Results No. of
patients
Percentage % reduction in PASI
score at 16 weeks
Excellent 12 60.00 100
Good 5 25.00 75-100
Moderate - - 50-75
Poor response 1 5.00 <50
Discontinued 2 10.00 -
Therefore in NBUVB group 60.0% of patients had excellent
response and 25.0 % of patients had good response at 16 weeks. 5.0% had
poor response
Response to therapy in PUVASOL group
3 patients had complete clearance at 16 weeks and  12 had good
response, 3 patients had poor response. 2 patient discontinued therapy due
to unknown reasons.
Therefore in PUVASOL group 15 % of patients had excellent
response and 60 % of patients had good response at 16 weeks. 15% had
poor response
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Table 16
Response to treatment in PUVASOL group
Results
No. of
patients Percentage
% reduction in
PASI score at 16
weeks
Excellent 3 15.00 100
Good 12 60.00 75-100
Moderate - - 50-75
Poor response 3 15.00 <50
Discontinued 2 10.00 -
SIDE EFFECTS
In PUVA group
? 3 patients developed erythema
? 3 patients developed burning sensation
? 2 patients had nausea
? 1 patient had pruritis
             In NBUVB group
? 3 patients developed erythema
?  3 patients developed initial exacerbation
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In PUVASOL group
? 3 patients developed erythema
?  3 patients developed nausea
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Figure 12 - showing adverse effects in three groups
PUVA NBUVB PUVASOL
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PUVA THERAPY
74
BEFORE
TREATMENT
SAME PATIENT AFTER 4 WEEKS OF TREATMENT
75
SAME PATIENT AFTER 8 WEEKS OF TREATMENT
SAME PATIENT AFTER 12 WEEKS OF TREATMENT
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               SAME PATIENT AFTER 16 WEEKS OF TREATMENT
77
BEFORE TREATMENT
SAME PATIENT AFTER 12  WEEKS OF TREATMENT
78
SAME PATIENT AFTER 16 WEEKS OF TREATMENT
79
NBUVB THERAPY
80
BEFORE TREATMENT
SAME PATIENT AFTER 8 WEEKS OF
TREATMENT
81
               SAME PATIENT AFTER 16 WEEKS OF TREATMENT
BEFORE TRAETMENT
82
AFTER 12 WEEKS OF
TRAETMENT
83
PUVASOL THERAPY
84
BEFORE TREATMENT
SAME PATIENT AFTER 12  WEEKS OF TREATMENT
85
BEFORE TREATMENT
AFTER 8 WEEKS OF
TREATMENT
86
AFTER 12 WEEKS OF
TREATMENT
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PHOTOTHERAPY UNIT
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DISCUSSION
          Psoralen ultraviolet A therapy, Narrow band ultraviolet B therapy
and PUVASOL are the standard therapeutic regimens available for the
management of psoriasis.
          There are few studies which compares the therapeutic efficacy of
PUVA and NBUVB in treatment of psoriasis. No studies have compared
the efficacy of PUVSOL with PUVA and NBUVB.
          So the present study compares the therapeutic efficacy of PUVA,
NBUVB and PUVASOL in the management of psoriasis.
          We enrolled 60 patients with chronic plaque type psoriasis involving
more than 20% body surface area for the study. They were randomly
divided into three groups.
           All  three  groups  were  well  matched  in  terms  of  age,  duration  of
lesions and baseline PASI score. They were followed up weekly after
initiating treatment. PASI score were calculated at 0, 4, 8, 12 and 16
weeks.
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COMPARISION OF PUVA WITH NBUVB GROUP
In PUVA group the mean baseline PASI score is 32.20 and mean
PASI score at 16 weeks is 0.38. Therefore there is 98.9% reduction in
PASI score at end of 16 weeks. In NBUVB group the mean baseline PASI
score is 31.04 and at mean PASI score at 16 weeks is 0.83. Therefore there
is 97.9% reduction in PASI score at end of 16 weeks. From above data it is
inferred that both groups showed good clearance of lesions after 16 weeks.
The p value is 0.694 which is not statiscally significant.
However the mean cumulative dose for NBUVB (17.10 J/cm2) is
less than the mean cumulative dose for PUVA (21.00 J/cm2).
          So both PUVA and NBUVB therapy produces clearance of lesions
with equal efficacy, however the mean cumulative dose is lower for
NBUVB. This observation in our study is similar to the study conducted
by Gordon et al81 who did a randomized control study in 100 patients with
plaque type psoriasis. An Indian study conducted by Dayal S et al82 from
Haryana also shows similar results.
The mean number of exposure in PUVA group is 14.72 weeks and
14.88 weeks in NBUVB group which is more or less equal. Markham et
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al83 in his study showed that the mean number of exposure is lower in
PUVA group than that of NBUVB group.
Koo  et  al84 reported that tazarotene plus NBUVB phototherapy is
significantly more effective than NBUVB phototherapy alone for
treatment of psoriasis.
COMPARISION OF PUVA WITH PUVASOL GROUP
In PUVA group the mean baseline PASI score is 32.20 and mean
PASI score at 16 weeks is 0.38. Therefore there is 98.9% reduction in
PASI score at end of 16 weeks. In PUVASOL group the mean baseline
PASI score is 31.59 and mean PASI score at 16 weeks is 7.76. Therefore
there is 75.44% reduction in PASI score at end of 16 weeks. From above
data it is inferred that PUVA group showed better clearance of lesions
after 16 weeks when compared to PUVASOL group. The p value < 0.005
this is statistically significant.
          So PUVA therapy produces clearance of lesions with greater
efficacy when compared to PUVASOL.
The mean number of exposure in PUVA group is 14.72 weeks and
18.97 weeks in PUVASOL group which again shows PUVA therapy
clears the lesion early when compared to PUVASOL therapy.
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          In our  study  15%  of  patients  in  PUVASOL  showed  complete
clearance of lesions, and 70% of patients showed marked improvement of
lesions.  In  a  study  conducted  by  Kar  PK  et  al85 showed PUVASOL
showed complete clearance in 32% of patients, marked improvement in
44% of patients and poor response in 24% of patients.
15 % of the patients in PUVASOL group showed poor response to
treatment in our study, where as in study conducted by Sadhan Kumar
Ghosh  et  al 86 showed 60% of patients had poor response. They also
showed that PUVASOL with methotrexate gives better results than
PUVASOL therapy alone.
The mean number of exposure in PUVA group is 14.72 weeks and
18.97 weeks in PUVASOL group. This shows PUVASOL therapy takes
long time to clear the lesion.
COMPARISION OF NBUVB WITH PUVASOL GROUP
In NBUVB group the mean baseline PASI score is 31.04 and mean
PASI score at 16 weeks is 0.83. Therefore there is 97.9% reduction in
PASI score at end of 16 weeks. In PUVASOL group the mean baseline
PASI score is 31.59 and at mean PASI score at 16 weeks is 7.76.
Therefore there is 75.44 % reduction in PASI score at end of 16 weeks.
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          From above data it is inferred that NBUVB showed better results in
terms of clearance of lesions when compared to PUVASOL therapy after
16 weeks. The p value is <0.005 which is statistically significant.
So NBUVB therapy produces better clearance of lesions than
PUVASOL therapy.
The mean number of exposure in NBUVB group is 14.88 weeks and
18.97 weeks in PUVASOL group. This shows PUVASOL therapy takes
long time to clear the lesion.
POOR RESPONSE
Poor response was seen in 1 patient in NBUVB group and 3 patients
in PUVASOL group. In PUVA group none had poor response. In our
study it has no correlation with baseline PASI score.
SIDE EFFECTS
The adverse effects in our study were minimal. The common side
effects were erythema, nausea, initial exacerbation and pruritis. The
adverse effect profile observed in our study was similar to that reported in
the literature.
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            Markham and Collins86 in their study showed that both PUVA and
NBUVB therapy are erythemogenic. They also reported that other side
effects like nausea, headache, pruritis and alopecia were commonly
observed in PUVA group. The above observation is similar to the present
study.
Sadhan  Kumar  Ghosh  et  al85 reported that erythema, nausea and
vomiting were common side effect with PUASOL therapy. Our study also
shows similar results.
Initial exacerbation was noted in 3 of our patients in NBUVB group,
but newer lesions ceased to appear with continuation of therapy. This
could be due to immunomodulatory effect of NBUVB.
Pruritis  was  noted  in  one  of  our  patients  in  PUVA  group  which
subsided with regular use of emollients and continuation of therapy. It is
assumed to be related to prostaglandin release.
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CONCLUSION
? PUVA therapy is an effective modality of treatment in chronic
plaque type psoriasis.
? NBUVB therapy has equal efficacy to PUVA therapy in our study.
? The mean cumulative dose is almost equal for both PUVA and
NBUVB therapy.
? However the mean number of exposure is less for PUVA group
when compared to NBUVB group.
? When PUVA and NBUVB are compared there is no statistically
significant difference in mean PASI score reduction at 16 weeks.
The percentage of reduction of mean PASI  at 16 weeks in PUVA
group is 98.9% and in NBUVB group is 97.9%. So both are almost
equally effective. But when duration of treatment is taken into
account PUVA therapy scores over the NBUVB therapy.
? When PUVA and  NBUVB therapy  are  compared  with  PUVASOL
the rate of clearance of lesions in later group is poor.
? All the side effects noted in our study were minor and they were
treated conservatively.
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? In conclusion our study has shown that both PUVA and NBUVB
groups achieved >75% or complete clearance at end of 16 weeks
when compared to PUVASOL group. But PUVA group achieved
faster clearance with less number of exposures as compared to
NBUVB group.
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COMPARATIVE STUDY OF THERAPEUTIC EFFICACY OF
PUVA, NBUVB AND PUVASOL IN THE TREATMENT OF
CHRONIC PLAQUE TYPE PSORIASIS
PROFORMA
Name: Date:
Age: Op No:
Sex: Case No:
Occupation :
Address:
HISTORY:
Duration:
Itching: Yes: No:
H/O Previous
treatment:
Topical: Systemic:
EXACERBATION WITH:
1. Cold climate 6. Emotional factors
2. Sunlight 7. Pregnancy
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3. Dialysis 8. Puberty
4. Infection 9. Menopause
5. Trauma
PAST HISTORY:
Hypertension Diabetes mellitus Tuberculosis
Photosensitivity Cutaneous malignancy Radiotherapy
DRUG TAKEN FOR ANY OTHER CONDITION:
Yes No
If yes
Name of the drug:
Duration of treatment:
FAMILY HISTORY:
Father: Mother:
Siblings: Others:
No. OF CHILDREN:
Male: Female:
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PERSONAL HISTORY:
Smoking: Alcohol:
MENSTRUAL HISTORY:
PREGNANCY: LACTATION:
GENERAL EXAMINATION:
1.  Pallor
2. Icterus
3. Edema
4. Pulse
5. Blood pressure
6. Weight
SYSTEMIC EXAMINATION:
CVS
RS
P/A
CNS
ENT
DENTAL
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DERMATOLOGICAL EXAMINATION:
Skin lesions Site
Morphology
Surface area involved
Auspitz sign – yes/no
Mucous
membrane
Scalp
Hair
Nail
Joint involvement
AREA &SEVERITY ASSESSMENT BY PASI SCORING:
Erythema / Infiltration / Desquamation
scoring
Area scoring
0- Nil 0- Nil
1- Mild 1- 0-9%
2- Moderate 2- 10-29%
3- Severe 3- 30-49%
4- Very severe 4- 50-69%
5- 70-89%
6- 90-100%
PASI was calculated as follows
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PASI = 0.1(EH+IH+DH) AH + 0.2(EU+IU+DU) AU +
       0.3(ET+IT+DT) AT + 0.4(EL+IL+DL)
A – Area H – Head T – Trunk
U – Upper limb L - Limb
INVESTIGATIONS:
Ophthalmological examination:
Total count:
Differential count:
ESR:
Hb:
Blood sugar:
Urea:
Creatinine:
Serum calcium:
Serum uric acid:
Blood VDRL:
HIV:
LFT:
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PUVA CHART
Date Cycle Dose Duration Cumulative dose Side
effects
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NBUVB CHART
Date Cycle Dose Duration Cumulative dose Side
effects
FOLLOW UP
Weeks PASI score Cumulative dose
0
4
8
12
16
1PUVA
S.No AGE SEX DURATION F/H SCALP MM NAIL JOINT PASI0 PASI 4
PASI
8 PASI 12
PASI
16
NO.OF
EXPO
WEEKS
OF
EXPO
CD SE
1 20 F 1 YEAR N Y N N N 38 20.3 12 6.3 0 28 14 20.5 E
2 30 M 4 YEARS N Y N P,R,SUH N 24 16.3 8.4 2.1 0.8 36 18 24 NA
3 30 M 3 MONTHS N N N N N 27.6 10.2 2.7 0 0 20 10 25 E
4 45 M 1.5 MONTH N Y N N N 40.8 32.6 16.4 10.5 2.1 42 21 27.5 BS
5 47 F 2 YEAR N N N P N 28.4 20.4 12.6 2.2 0 26 13 19 NIL
6 32 M 1 YEAR N N N N N 32.8 24.2 9.4 1.1 0 26 13 19 PR
7 32 M 6 MONTH N N N N N 35.2 25.2 13.5 6.4 1.2 38 18 16 NIL
8 19 M 2 MONTH N N N N N 18 9.4 1.2 0 0 18 9 15.5 NIL
9 56 F 2 YEARS Y Y N P Y 32 23 8.6 1.2 0 26 13 19 NIL
10 42 F 1 YEAR N N N N N 33.6 21.6 16.2 4.6 2.7 44 22 28 B.S
11 36 M 8 MONTH N N N N N 43.5 28.8 DISCONTINUED NIL
12 53 M 1.5 YEAR N Y N N N 39 26.4 DISCONTINUED NIL
13 21 M 7 MONTHS Y N N N N 26.4 18.8 8.1 0 0 22 11 17.5 NIL
14 26 M 4 MONTHS N N N N N 27 17.3 11.2 4.7 0 44 22 28 NA
15 50 MM 3 YEARS N Y N P,R,SUH Y 42.3 31.1 21.4 9.6 0.1 34 17 23.5 B.S
16 45 F 2 YEARS Y N N P N 44 24.6 14.3 4.2 0 30 15 21 NIL
17 61 M 4 YEARS N N N P N 34.2 18.4 9.6 1.1 0 26 13 19 NIL
18 38 M 6 MONTHS N N N N N 19.2 10.8 4.6 0 0 20 10 16.5 NIL
19 36 M 8 MONTHS N N N N N 28.4 16.3 9.4 0 0 24 12 18.5 NIL
20 42 F 1 YEAR N N N N N 29.6 19.4 10.1 3.3 0 28 14 20.5 E
2NBUVB
S.No AGE SEX DURATION F/H SCALP MM NAIL JOINT
PASI
0 PASI 4
PASI
8
PASI
12
PASI
16
NO.OF
EXPO
WEEKS
OF
EXPO CD SE
1 46 F 2 YEARS N N N SUH N 19.2 10.8 2.4 1 0 45 15 17.25 NIL
2 33 M 2 MONTHS N Y N N N 31.6 23.6 14.7 6.8 1.2 54 18 19.5 NIL
3 49 M 5 YEARS N N N P N 27.6 10.2 2.7 0 0 30 10 13.5 NIL
4 55 M 6 YEARS N N N N N 34.2 27.2 17.4 10.4 4.1 63 21 21.75 E
5 20 F 3 MONTHS N Y N P N 31.5 28.1 19.4 7.6 0 42 14 16.5 NIL
6 21 M 1 YEAR Y N N N N 39 26.4 10.8 4.2 0 42 14 16.5 NIL
7 28 F 3 YEARS N Y N P N 40.8 35.6 21 9.6 2.1 57 19 20.25 E
8 23 M 6 MONTHS N N N P N 15.2 10.1 1.5 0 0 30 10 13.5 NIL
9 29 F 2 YEARS N N N N N 42 24.1 10.4 4.8 2.1 57 19 20.25 NIL
10 17 M 9 MONTHS N N N N N 26.4 20.8 8.1 0 0 33 11 14.25 NIL
11 59 M 4 YEARS Y Y N SUH Y 46.4 32.4 20.8 12.8 4.6 66 22 23.5 NIL
12 55 F 2 YEARS N Y N P N 34.8 30.2 26.4 20.8
POOR
RESPONSE   NIL
13 25 M 1 MONTH N N N N N 19.2 10.8 4.6 0 0 30 10 13.5 NIL
14 63 M 8 MONTHS N Y N P Y 21.2 18.4 12.6 8.2 0 42 14 16.5 IE
15 46 M 8 YEARS N Y N P N 47.8 DISCONTINUED   NIL
16 28 M 2 MONTHS N N N N N 30.2 15.2 10.4 4.2 0 42 14 16.5 NIL
17 49 M 6 MONTHS N N N N N 31.2 16.5 7.2 1.3 0 39 13 15.75 NIL
18 40 M 3 YEARS Y Y N SUH Y 24.9 14.7 7.4 3 0 45 15 15.25 IE
19 30 F 5 MONTHS N N N N N 26 16.3 11.4 4.6 0 42 14 16.5 IE
20 45 F 6 MONTHS N N N N N 31.6 24.2 18.4 13.2
POOR
RESPONSE   NIL
3PUVASOL
S.No AGE SEX DURATION F/H SCALP MM NAIL JOINT
PASI
0
PASI
4 PASI 8 PASI 12
PASI
16
NO.OF
EXPO
WEEKS
OF EXPO SE
1 57 M 4 MONTHS N Y N N Y 44 42.6 38.4 36.7 32.4 POOR RESPONSE NIL
2 34 F 1 YEAR N N N P N 28.4 24.6 20.7 13.2 4.6 63 21 E
3 30 M 6 MONTHS N Y N N N 31.8 26.8 19.4 11.3 3.1 60 20 NA
4 40 F 8 MONTHS N N N N N 41.8 37.8 21.4 12.6 3.1 60 20 NIL
5 32 F 8 YESRS N N N N N 36.8 24.8 18.4 12.2 4.1 63 21 E
6 45 F 2 YEARS N N N P N 29.6 19.4 10.2 3.2 0 45 15 NIL
7 25 F 8 MONTHS N N N N N 21.6 16.2 7.2 5.4 0.9 54 18 NIL
8 37 F 2 MONTHS N N N N N 25.2 18 10.8 8.1 0 48 16 NIL
9 44 M 2 YEARS N N N P,SUH Y 38.2 DISCONTINUED NIL
10 35 M 4 MONTHS N N N N N 36 34.8 32.4 30.6 28.3 POOR RESPONSE NIL
11 38 M 9 MONTHS N N N N N 40.2 31.8 24.6 14.5 5.8 69 23 E
12 42 M 2 YEARS Y Y N P,SUH Y 42.3 39.2 36.4 33.5 30.1 POOR RESPONSE NIL
13 58 M 5 MONTHS N N N N N 21.6 15.2 6.2 3.4 0 48 16 NIL
14 32 F 1 YEAR Y N N N N 28 15.8 11.4 6.3 1.1 57 19 NA
15 40 M 3 YEARS N N N P,SUH Y 36 28.8 14.4 9 1.8 60 20 NIL
16 53 F 1.5 YEARS N N N N N 35.2 26.4 DISCONTINUED NIL
17 37 F 6 MONTHS N N N N N 18.9 12.4 7.3 4.2 4.2 51 17 NIL
18 31 M 7 MONTHS N Y N P N 21 18.6 11.4 7.3 7.3 60 20 NA
19 36 M 9 MONTHS N N N N N 34.2 24.6 16.4 10.8 10.8 60 20 NIL
20 43 M 2 YEARS Y Y N P,R,SUH N 21 16.4 11.8 2.1 2.1 54 18 NIL
1KEY TO MASTER CHART
?  M- MALE
?  F- FEMALE
? F/H – FAMILY  HISTORY
? MM- MUCOUS MEMBRANE INVOLVEMENT
? Y – YES
? N – NO
? P – PITTING
? R – RIDGING
? SUH – SUBUNGUAL HYPERKERATOSIS
? PASI – PSORIASIS AREA AND SEVERITY INDEX
? CD – CUMULATIVE DOSE
? SE – SIDE EFFECTS
? E – ERYTHEMA
? PR – PRURITIS
? NA – NAUSEA
? IE – INITIAL EXACERBATION
2ABBREVIATIONS
? PUVA – PSORALEN ULTRAVIOLET A
? NBUVB – NARROW BAND ULTRAVIOLET B
? PUVASOL – PSORALEN ULTRAVIOLET  SOLAR
THERAPY
? PASI – PSORIASIS AREA AND SEVERITY SCORE
? MED – MINIMAL ERYTHEMA DOSE
? MPD – MINIMUM PHOTOTOXIC DOSE

